Curanex Expands Pipeline to Address $3.9B Cancer Cachexia Market
Curanex expands its drug pipeline to include cancer cachexia, targeting a market worth $2.54 billion in 2024 and projected to reach $3.90 billion by 2033. Lead candidate Phyto-N is in preclinical studies for ulcerative colitis while Curanex pursues therapies for syndrome affecting up to 80% of cancer patients with no approved treatments.
1. Company Expands Pipeline
Curanex has broadened its pipeline to include cancer cachexia, marking its seventh core indication alongside ulcerative colitis, atopic dermatitis and others. This strategic move reflects the company’s shift toward supportive oncology therapies to address serious treatment gaps.
2. Market Opportunity
Cancer cachexia affects up to 80% of advanced cancer patients and currently lacks approved US treatments. The global market is valued at $2.54 billion in 2024 and expected to grow to $3.90 billion by 2033, presenting a significant commercial opportunity.
3. Lead Candidate Progress
Phyto-N, Curanex’s lead candidate, is in preclinical studies ahead of an IND submission for ulcerative colitis. Concurrently, the company is evaluating novel approaches to treat cancer cachexia by leveraging its expertise in inflammation and metabolic dysfunction.